Market research
MYL Mylan N.V
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9B
- P/E ratio
- 30.73
- Analyst target
- 21.75
- Dividend yield
- 0.0%
- Beta
- 1.47
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- USN594651093
- Market cap
- 9B
- P/E ratio
- 30.73
- Analyst target
- 21.75
- Dividend yield
- 0.0%
- Beta
- 1.47
About
About Mylan N.V
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MYL discussion.
5 years, 4 months ago
Viatris Inc is currently in a long term downtrend where the price is trading 99.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
Viatris Inc's total revenue rose by 0.4% to $3B since the same quarter in the previous year.
Its net income has increased by 2.1% to $186M since the same quarter in the previous year.
Finally, its free cash flow grew by 4.6% to $466M since the same quarter in the previous year.
Based on the above factors, Viatris Inc gets an overall score of 4/5.